홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
Русский
English
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PDSB
#3621
PDS Biotechnology Corporation Common Stock
0.6
8
-1.45%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-1.45%
월간 변동
-32.00%
6달 변화
-47.29%
년간 변동율
-52.45%
이전 종가
0.6
9
Open
0.6
8
Bid
Ask
Low
0.6
8
High
0.6
8
양
6
마켓
주식
헬스케어
PDSB
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
37.41 M
45.4 M
45.71 M
46.63 M
48.98 M
—
Valuation ratios
Enterprise value
93.1 M
32.3 M
14.39 M
30.12 M
23.27 M
100.08 M
Price to earnings ratio
-3.26
-1.58
-1.27
-1.45
-1.23
-5.53
Price to sales ratio
—
—
—
—
—
—
Price to cash flow ratio
-3.75
-1.7
-1.31
-1.54
-1.31
-5.85
Price to book ratio
1.14
3.13
0.47
0.66
0.62
4.88
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
-0.2
-0.18
-0.18
-0.23
-0.26
-0.85
Return on equity %
-0.49
-0.42
-0.38
-0.59
-0.95
-2.34
Return on invested capital %
-343.75
-228.73
-273.13
-206.74
-258.04
-966.63
Gross margin %
—
—
—
—
—
—
Operating margin %
—
—
—
—
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
—
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
2.84
2.64
2.33
2.92
2.09
9.97
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
—
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.23
0.2
0.14
0.32
0.34
1
Long term debt to total equity ratio
0.55
0.48
0.28
0.81
1.26
2.84
Per share metrics
Operating cash flow per share
-0.22
-0.23
-0.22
-0.2
-0.13
-0.77
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
1.35
1.14
0.99
0.69
0.56
3.39
Net current asset value per share
1.42
1.24
1.05
0.73
0.6
3.61
Tangible book value per share
0.6
0.52
0.55
0.35
0.2
1.62
Working capital per share
0.92
0.77
0.6
0.48
0.31
2.16
Book value per share
0.6
0.52
0.55
0.35
0.2
1.62
뉴스
PDS Biotech изменяет протокол исследования фазы 3
PDS Biotech amends Phase 3 trial to add accelerated approval path
PDS Biotech сообщает о 9,6-месячной выживаемости при раке простаты
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study
PDS Biotech получает патент на иммунотерапию рака PDS0101
PDS Biotech secures patent for cancer immunotherapy PDS0101
Акции PDS Biotech взлетели после встречи с FDA
PDS Biotech stock soars after FDA meeting provides accelerated approval path
PDS Biotech подает измененный протокол для 3 фазы испытания рака
PDS Biotech submits amended protocol for phase 3 cancer trial
PDS Biotech secures new patent for cancer immunotherapy in Japan
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why